Companies Agree to Continue HIV Drug Safety Studies

Important note: Information in this article was accurate in 2002. The state of the art may have changed since the publication date.

Companies Agree to Continue HIV Drug Safety Studies

Reuters Health (12.16.02) - Wednesday, December 18, 2002
Richard Woodman

Pharmaceutical companies have agreed to continue studies for at least another year to assess whether HIV medicines increase the risk of heart disease and other complications, an AIDS specialist said Monday. Last month during an HIV congress in Glasgow, HIV/AIDS groups voiced concerns that manufacturers would stop funding studies into the side effects of highly active antiretroviral treatment before the extent of any increased risk could be determined. The European AIDS Treatment Group also expressed its worries to the Steering Committee on the Metabolic Complications of HAART, which includes company representatives as well as researchers and regulators. "I think we can confidently say now that we have funding agreed for a further year from all the companies involved and for a second year from most," said British committee member Professor Ian Weller, of University College- London. The studies of metabolic complications were launched in 1999 at the request of the European Medicines Evaluation Agency. AIDS activists say patients may have to be followed for decades to obtain definitive answers about the long- term risks of therapy.
021218
AD022452

Copyright © 2002 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.